Quantitative detection of IDH2 mutation for minimal residual disease monitoring in patients with acute myeloid leukemia and its comparison with mutations in NPM1 gene

Leukemia and Lymphoma

Volumn 54, Issue 4, 2013, Pages 867-870

  Jeziskova, Ivana ^a   Razga, Filip ^a   Toskova, Martina ^a   Dvorakova, Dana ^a,b   Timilsina, Shira ^a   Mayer, Jiri ^a,b   Racil, Zdenek ^a,b  

^a UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^b MASARYK UNIVERSITY   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; DAUNORUBICIN; ISOCITRATE DEHYDROGENASE 2; MITOXANTRONE; NUCLEOPHOSMIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALLELE; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ENZYME ACTIVITY; EXON; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; LETTER; MALE; MINIMAL RESIDUAL DISEASE; PATIENT MONITORING; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SOMATIC MUTATION;

HUMANS; ISOCITRATE DEHYDROGENASE; LEUKEMIA, MYELOID, ACUTE; MUTATION; NEOPLASM, RESIDUAL; NUCLEAR PROTEINS;

EID: 84879544462     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2012.727414     Document Type: Letter

References (15)

1. Teff eri A, Lasho T L, Abdel-Wahab O, et al. IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fi brotic-or blast-phase essential trombocythemia, polycythemia vera or myelofi brosis. Leukemia 2010; 24: 1302-1309.
2. Th ol F, Weissinger EM, Krauter J, et al. IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis. Haematologica 2010; 95: 1668-1674.
3. Mardis D, Ding L, Dooling DJ, et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 2009; 361: 1058-1066.
4. Paschka P, Schlenk RF, Gaidzik VI, et al. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. J Clin Oncol 2010; 28: 3636-3643.
5. Gross S, Cairns RA, Minden MR, et al. Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. J Exp Med 2010; 207: 339-344.
6. Ward PS, Patel J, Wise DR, et al. The common feature of leukemiaassociated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting 〈 -ketoglutarate to 2-hydroxyglutarate. Cancer Cell 2010; 17: 225-234.
7. Teff eri A, Jimma T, Sulai N H, et al. IDH mutations in primary myelofi brosis predict leukemic transformation and shortened survival: Clinical evidence for leukemogenic collaboration with JAK2V617F. Leukemia 2012; 26: 475-480.
8. Th ol F, Damm F, Wagner K, et al. Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia. Blood 2010; 116: 614-616.
9. Green CL, Evans CM, Zhao L, et al. The prognostic signifi cance of IDH2 mutations in AML depends on the location of the mutation. Blood 2011; 118: 409-412.
10. Chou WC, Peng KY, Lei WC, et al. Persistence of mutant isocitrate dehydrogenase in patients with acute myeloid leukemia in remission. Leukemia 2011; 26: 527-529.
11. Jeziskova I, Razga F, Bajerova M, et al. IDH2 mutations in patients with acute myeloid leukemia: Missense p.R140 mutations are linked to disease status. Leuk Lymphoma 2010; 51: 2285-2287.
12. Dvorakova D, Racil Z, Jeziskova I, et al. Monitoring of minimal residual disease in acute myeloid leukemia with frequent and rare patient-specific NPM1 mutations. Am J Hematol 2010; 85: 926-929.
13. Chiu RWK, Murphy MF, Fidler C, et al. Determination of RhD zygosity: Comparison of a double amplifi cation refractory mutation system approach and a multiplex real-time quantitative PCR approach. Clin Chem 2001; 47: 667-672.
14. Dohner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults: Recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010; 115: 453-474.
15. Yen K E, Bittinger M A, S u S M, et al. Cancer-associated IDH mutations: Biomarker and therapeutic opportunities. Oncogene 2010; 29: 6409-6417.